Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant cemiplimab versus placebo after surgery and radiation for high-risk cutaneous squamous cell carcinoma
2024-511653-22-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in cutaneous squamous cell carcinoma (cSCC) comparing Cemiplimab with Placebo (2 arms). Primary endpoint: Disease-free survival. Planned start Feb 2020; status: authorised.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2024-511653-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511653-22-00.